Company / PP&E (Net)
Supernus Pharmaceuticals, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$10.5M
FY2025
5-year range
$10.5M / $17.0M
FY2021-FY2025
Trend
-8.8%
vs FY2024
Sector context
#95 of 193
Health Care
What the data says
At $11M, Supernus Pharmaceuticals, Inc.'s pp&e (net) ranks #95 of 193 in the Health Care sector. PP&E (Net) has declined for 5 consecutive years, from $38M in FY2020 to $11M in FY2025.
Based on SEC 10-K filings.
$11M in FY2025 with a 5-year CAGR of -22.6%.
Declined from $14M to $11M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -11.5%
- 5-Year CAGR
- -22.6%
- 10-Year CAGR
- -
Sector benchmark
#95 of 193 in Health CareTop 49% of 193This company $10.5M Sector average $777.6M
▼
-98.6% below sector average
Key checks
Key Insights
- Supernus Pharmaceuticals, Inc.'s pp&e (net) has declined for 5 consecutive years.
- 5-year CAGR of -22.6%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 8.8% year-over-year.
- Ranks #95 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.5M | -8.8% |
| FY2024 | $11.5M | -14.7% |
| FY2023 | $13.5M | -10.8% |
| FY2022 | $15.2M | -10.5% |
| FY2021 | $17.0M | -55.2% |
| FY2020 | $37.8M | +121.6% |
| FY2019 | $17.1M | +316.8% |
| FY2018 | $4.1M | -20.1% |
| FY2017 | $5.1M | +18.0% |
| FY2016 | $4.3M | +12.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026